Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) represents the most prevalent subtype of advanced breast cancer in postmenopausal women. Here, ERBB2 is linked to breast carcinoma.